Strongbridge Biopharma plc Announces Top-Line Results from Extended Evaluation Phase of the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome
11 mars 2019 07h30 HE
|
Strongbridge Biopharma plc
~ Extended Evaluation Phase Meets Objective of Showing Positive Long-Term Benefit-Risk Profile of RECORLEV™ (levoketoconazole) ~ ~ Favorable Liver-Related Findings: No Patients Experienced an...
Strongbridge Biopharma plc Announces New Employment Inducement Awards
08 mars 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 Annual Meeting of the Endocrine Society (ENDO)
04 mars 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference
27 févr. 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2018 Financial Results
26 févr. 2019 07h30 HE
|
Strongbridge Biopharma plc
~ RECORLEV™ (levoketoconazole) Phase 3 Clinical Program and Type C FDA Meeting in First Quarter Progressing as Planned ~ ~ $145 Million Upfront Cash Payment and $36.7 Million Equity Investment from...
Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders
22 févr. 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call on February 26, 2019
19 févr. 2019 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada
19 déc. 2018 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
Strongbridge Biopharma plc Announces Presentation of New Data Comparing the In Vitro Effects of Levoketoconazole, the Active Ingredient in RECORLEV™, and Ketoconazole on Human Cortisol Production
20 nov. 2018 07h30 HE
|
Strongbridge Biopharma plc
In Vitro Data Show Preliminary Evidence That Levoketoconazole Inhibits ACTH Secretion and May Have Anti-Tumor Effect on Pituitary Adenoma Cells First Study in Primary Human Adrenal Cells Suggests...
Strongbridge Biopharma plc to Present at the Stifel 2018 Healthcare Conference
05 nov. 2018 16h15 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...